Safety and Visual Function of Suprachoroidal CLS-TA versus Real World Rescue Therapies for Macular Edema associated with Noninfectious Uveitis: A Post-hoc Analysis

Pouya Dayani, MD¹

Colette Hall, MD²

Thomas A. Ciulla, MD, MBA²


1. Retina-Vitreous Associates Medical Group

2. Clearside Biomedical, Inc.

<u>Financial Disclosures</u> PD: Alimera, Eyepoint, Novartis, Regeneron CH, TC: Clearside Biomedical, Employee & Shareholder The Retina Society 54th Annual Scientific Meeting September 29 – October 2, 2021

PEACHTREE: Phase 3, Randomized, Controlled, Double-Masked, Multicenter Trial

CLS-TA: Proprietary triamcinolone acetonide for suprachoroidal injection



The Suprachoroidal Space (SCS) *Targeted and Compartmentalized Delivery*



Key Inclusion and Exclusion Criteria

Inclusion

- Diagnosis of macular edema with central subfield thickness ≥300 microns on SD-OCT
- Noninfectious uveitis of any associated diagnosis/etiology
- Any anatomic location: anterior, intermediate, posterior and panuveitis
- Visual acuity: 20/800 to 20/40 (≥5 to ≤70 ETDRS letters)


Exclusion

- Any active ocular disease or infection in the study eye other than uveitis
- Intraocular pressure >22 mmHg or uncontrolled glaucoma; patients ≤22 mmHg could be on up to 2 IOP-lowering medications

Subjects could have active or controlled disease at enrollment

PEACHTREE: Met Primary Efficacy Endpoint

Primary Endpoint: Subjects gaining ≥15 BCVA letters from baseline at Week 24, %



Intention-to-treat population; Last Observation Carried Forward imputation.

The p-value is based on a Cochran-Mantel-Haenszel test for general association between treatment and response with stratification by country.



IOP-Related Events	CLS-TA N = 96	Control N = 64
Elevated IOP adverse events	11 (11.5%)	10 (15.6%)
IOP elevation ≥10 mmHg change from baseline at any visit*	9 (9.4%)	7 (10.9%)
IOP elevation ≥30 mmHg absolute reading at any post baseline visit*	5 (5.2%)	4 (6.3%)
Given any additional IOP-lowering medication	7 (7.3%)	6 (9.4%)
Any surgical intervention for an elevated IOP Adverse Event	0	0

One serious ocular AE


- Retinal detachment 8 weeks after CLS-TA, in different quadrant
- Determined to be unrelated to study drug by the Investigator

Cataract: 7.3% (7/96) in the CLS-TA arm vs. 6.3% (4/64) in the sham arm

Safety population; includes patients in the control group who received rescue medication *Based on elevated intraocular pressure adverse reactions

Rescue Therapy Rates: CLS-TA (13.5%) vs. Control (71.8%)

Most Targeted (Localized) Subsequent Medication* Used Rates, CLS-TA vs. Control



*Rescue medications classified by most targeted type of therapy used during study, where:

Intravitreal Corticosteroid > Periocular corticosteroid > Topical Corticosteroid > Systemic Corticosteroid > Topical NSAID

Post-Hoc Analysis.

Sub-Analysis by Rescue Status in PEACHTREE

Purpose: To compare outcomes between CLS-TA and real-world rescue therapies **Methods:** VA and safety in unrescued CLS-TA versus rescued control group


Two (2) subgroups analyzed:


	Unrescued Rescued	
CLS-TA	n=83/96 (86.5%)	n=13/96 (13.5%)
Control	n=18/64 (28.1%)	n=46/64 (71.9%)

Visual acuity in unrescued CLS-TA: Greater mean BCVA and more 3 line gainers at week 24










A significantly greater mean reduction in CST was observed for unrescued CLS-TA subjects versus rescued control subjects

Mean Change in CST by Week



At Week 24: CST reduction* in Unrescued CLS-TA subjects = 174.0 μm Rescued control subjects = 148.5 μm

(95% CI for difference -88.2 to -2.0 µm, P=0.040)

*in subjects who completed the study with gradable images

Safety: Treatment Emergent Adverse Events (TEAE)

	Unrescued CLS-TA n = 83	Rescued Control n = 46
% of subjects with ≥1 TEAE	48.2%	63.0%
AEs related to elevated IOP	10.8%	21.7%
Incidence of Cataract	4.8%	8.7%
IOP-related surgical interventions	none	none

Conclusion

- CLS-TA subjects vs. rescued control subjects:
 - significantly greater reduction in CST
 - trended towards greater BCVA improvement
 - lower incidence of IOP elevation and cataract
- This post hoc analysis represents a "real world" mix of rescue treatments, with expected limitations in terms of sample size, treatment type, etc.